CTOs on the Move

BridgeHealth

www.bridgehealth.com

 
BridgeHealth connects people with the nation`s best surgical care for a better experience, better outcomes, and better value. We offer a value-based approach to surgical care for self-insured plan sponsors and their members, saving them an average of 30% to 50% on procedures compared with PPO rates. BridgeHealth`s nationwide Centers of Excellence focus on quality outcomes and provide pre-negotiated bundled case rates for a broad scope of surgical procedures, including musculoskeletal, neurological, general surgery, cardiac, bariatric, and women`s health. BridgeHealth contracts with hospital providers who rank in the top quartile for their clinical specialty, based on outcomes and other objective ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Kris Jamsa
Chief Technology Officer Profile

Funding

BridgeHealth raised $40M on 10/22/2020

Similar Companies

Cornerstone Specialty Network

Cornerstone Specialty Network is a company that provides value to community-based oncology practices through network aggregation, delivering value-added opportunities that support independence and long-term sustainability for community oncology practices.

Lumilife

Lumilife is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

QueensCare Family Clinics

QueensCare Family Clinics is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. QueensCare Family Clinics is based in Los Angeles, CA. You can find more information on QueensCare Family Clinics at www.queenscare.org

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.

Healthify

At Healthify, we build the infrastructure to support end-to-end care coordination across our social service networks.